Evidence map›Paper›PMID 25282159›Full record

ArticleNature immunology2014

The ion channel TRPV1 regulates the activation and proinflammatory properties of CD4⁺ T cells.

Samuel Bertin, Yukari Aoki-Nonaka, Petrus Rudolf de Jong, Lilian L Nohara, Hongjian Xu, Shawna R Stanwood, Sonal Srikanth, Jihyung Lee, Keith To, Lior Abramson and 13 more

2 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 140 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04018924 nacompletednot on this mapstarted 2018, after this paper: background citation

Multi-center Study on the Effectiveness of Treatment With a Blue Light Medical Device (EmoLED) in Reduction of the Ulcer Surface in 10 Weeks

TypeinterventionalSponsorEmoledRan2018 to 2019Enrolled90ConditionsLeg Ulcers Venous, Dehiscence, Surgical WoundArmsIllumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)
NCT04689009 nacompletednot on this mapstarted 2019, after this paper: background citation

Multi-centre, Randomized Controlled, Prospective Study on the Speed of Healing, Life Quality and Cost-effectiveness of the Treatment With the Blue Light Medical Device EmoLED vs a Standard Treatment for Leg Ulcers (L.U.C.E. Study)

TypeinterventionalSponsorEmoledRan2019 to 2024Enrolled83ConditionsVenous Leg Ulcer, Mixed Leg UlcerArmsEmoLED, current Standards Of Care
3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 1 synthesis or guideline pooled it, 257 citations in OpenAlex.

  1. The Impact of TRPV1 on Cancer Pathogenesis and Therapy: A Systematic Review.International journal of biological sciences · 2021
    Pooled it
  2. Review
  3. Channels (Austin, Tex.) · 2026
    Article
  4. Article
  5. L-type voltage-gated CaEMBO reports · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. TRPV1+ neurons promote cutaneous immunity against Schistosoma mansoni.Journal of immunology (Baltimore, Md. : 1950) · 2025
    Article
  11. Article
  12. Review
  13. Metabolite Profiling and Anti-Inflammatory Activities ofMolecules (Basel, Switzerland) · 2025
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. TRPV1: The key bridge in neuroimmune interactions.Journal of intensive medicine · 2024
    Review
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 4 countries.

Samuel BertinDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Yukari Aoki-NonakaDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Petrus Rudolf de JongDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Lilian L Nohara *Michael Smith Laboratories; Centre for Blood Research; The Brain Research Centre; Department of Medical Genetics; Department of Microbiology and Immunology; Department of Zoology, University of British Columbia, Vancouver, BC, Canada.
Hongjian Xu *Michael Smith Laboratories; Centre for Blood Research; The Brain Research Centre; Department of Medical Genetics; Department of Microbiology and Immunology; Department of Zoology, University of British Columbia, Vancouver, BC, Canada.
Shawna R StanwoodMichael Smith Laboratories; Centre for Blood Research; The Brain Research Centre; Department of Medical Genetics; Department of Microbiology and Immunology; Department of Zoology, University of British Columbia, Vancouver, BC, Canada.
Sonal SrikanthDepartment of Physiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA.
Jihyung LeeDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Keith ToDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Lior AbramsonDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Timothy YuDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Tiffany HanDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Ranim ToumaDepartment of Pediatrics University of California, San Diego, La Jolla, CA 92093, USA.
Xiangli LiDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
José M González-NavajasDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Scott HerdmanDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Maripat CorrDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Guo FuDepartment of Immunology and Microbial Science, IMM1, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
Hui DongDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Yousang GwackDepartment of Physiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA.
Alessandra FrancoDepartment of Pediatrics University of California, San Diego, La Jolla, CA 92093, USA.
Wilfred A JefferiesMichael Smith Laboratories; Centre for Blood Research; The Brain Research Centre; Department of Medical Genetics; Department of Microbiology and Immunology; Department of Zoology, University of British Columbia, Vancouver, BC, Canada.
Eyal RazDepartment of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
University of California San Diego · USCanada's Michael Smith Genome Sciences Centre · CAUniversity of California, Los Angeles · USScripps Research Institute · US

Funding

TL MOLECULES AND GAMMA-DELTA T CELLSP01DK035108 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KAGNOFF, MARTIN FREDERICK · 1986 to 2013
$19.2M
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
Novel regulators of store-operated Ca2+ entry in immune systemsR01AI083432 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GWACK, YOUSANG · 2009 to 2020
$3.8M
Th17 subsets: Differential roles in immune defense mechanisms at the G-I mucosaU01AI095623 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RAZ, EYAL · 2011 to 2015
$1.6M
CIHR MOP-102698NIAID NIH HHS AI083432NIAID NIH HHS R01 AI083432NIAID NIH HHS U01 AI095623NIDDK NIH HHS P01 DK035108NIDDK NIH HHS P01 DK35108NINDS NIH HHS P30 NS047101
6 · The paper itself

Abstract

TRPV1 is a Ca(2+)-permeable channel studied mostly as a pain receptor in sensory neurons. However, its role in other cell types is poorly understood. Here we found that TRPV1 was functionally expressed in CD4(+) T cells, where it acted as a non-store-operated Ca(2+) channel and contributed to T cell antigen receptor (TCR)-induced Ca(2+) influx, TCR signaling and T cell activation. In models of T cell-mediated colitis, TRPV1 promoted colitogenic T cell responses and intestinal inflammation. Furthermore, genetic and pharmacological inhibition of TRPV1 in human CD4(+) T cells recapitulated the phenotype of mouse Trpv1(-/-) CD4(+) T cells. Our findings suggest that inhibition of TRPV1 could represent a new therapeutic strategy for restraining proinflammatory T cell responses.

Indexed as

AnilidesAnimalsCalciumCalcium ChannelsCalcium SignalingCapsaicinCD4-Positive T-LymphocytesCells, CulturedCinnamatesColitisHumansInflammationInterleukin-10IntestinesLymphocyte ActivationMiceAnilidesCalciumCalcium ChannelsCapsaicinCinnamatesIL10 protein, mouseInterleukin-10N-(3-methoxyphenyl)-4-chlorocinnamanilideReceptors, Antigen, T-CellSensory System AgentsTRPV1 protein, mouseTRPV Cation Channels

Identifiers

PMID25282159
PMCPMC4843825
OpenAlexW1981577795

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.